The North America Primary Immunodeficiency Diseases Treatment Market was valued at USD 2.8 Billion in 2024 and is projected to reach USD 4.5 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period (2024–2030). This growth is propelled by rising disease prevalence, improved diagnostic methods, and expanding treatment accessibility for rare immune disorders.
As healthcare prioritizes personalized medicine for immune deficiencies, biopharmaceutical firms are delivering breakthrough therapies across immunoglobulin replacement, gene correction, and cellular treatments. We profile the Top 10 Companies in the North America Primary Immunodeficiency Diseases Treatment Industry, spotlighting innovators transforming patient care through advanced biologics and precision medicine approaches.
🔟 1. Takeda Pharmaceutical Company Limited
Headquarters: Tokyo, Japan (North America HQ in Deerfield, IL)
Key Offering: HyQvia, Gammagard Liquid, Cuvitru
Takeda dominates the immunoglobulin therapy sector, commanding 32% of global IVIG market share. Their subcutaneous and intravenous products serve over 50,000 PID patients worldwide with proven clinical efficacy.
Therapeutic Advancements:
- Pioneering recombinant immunoglobulin technologies
- Expanding plasma collection network with 200+ centers
- Developing next-gen antibody replacement therapies
Download FREE Sample Report: North America Primary Immunodeficiency Diseases Treatment Market – View in Detailed Research Report
9️⃣ 2. CSL Behring
Headquarters: King of Prussia, PA, USA
Key Offering: Hizentra, Privigen, Berinert
CSL Behring operates the largest plasma collection network globally, processing over 50 million liters annually. Their 20% subcutaneous IG therapy (Hizentra) revolutionized home-based treatment administration.
Therapeutic Advancements:
- Novel IgG formulations with extended half-life
- Patient empowerment programs for self-administration
- Immune globulin production capacity expansion projects
8️⃣ 3. Grifols S.A.
Headquarters: Barcelona, Spain (North America HQ in Los Angeles, CA)
Key Offering: Gamunex-C, Flebogamma DIF, Xembify
Grifols leads in plasma-derived therapies with advanced fractionation technologies, producing treatments for over 100,000 PID patients annually across North America.
Therapeutic Advancements:
- High-purity immunoglobulin manufacturing processes
- Specialty pharmacy integration for treatment access
- Novel subcutaneous IgG delivery systems
7️⃣ 4. Octapharma AG
Headquarters: Lachen, Switzerland (U.S. HQ in Hoboken, NJ)
Key Offering: Octagam, Cuvitru, Wilate
Octapharma specializes in high-concentration immunoglobulin therapies, with products used in over 80 countries. Their PID pipeline includes next-generation recombinant factor treatments.
Therapeutic Advancements:
- Proprietary plasma protein purification technologies
- Patient support networks for treatment adherence
- Continuous manufacturing process innovations
Download FREE Sample Report: North America Primary Immunodeficiency Diseases Treatment Market – View in Detailed Research Report
6️⃣ 5. Kedrion Biopharma
Headquarters: Lucca, Italy (U.S. HQ in Fort Lee, NJ)
Key Offering: Kedrab, Gammaked, Alphanate
Kedrion has rapidly expanded its North American presence through strategic acquisitions, now supplying immunoglobulins to over 1,500 treatment centers.
Therapeutic Advancements:
- Plasma collection infrastructure development
- Biologic license application pipeline expansion
- Specialty distribution network growth
5️⃣ 6. ADMA Biologics, Inc.
Headquarters: Ramsey, NJ, USA
Key Offering: BIVIGAM, ASCENIV, Nabi-HB
ADMA Biologics operates FDA-licensed plasma collection and manufacturing facilities, specializing in high-titer immunoglobulin products for immune deficiencies.
Therapeutic Advancements:
- Vertical integration from plasma to finished product
- Hyperimmune globulin R&D programs
- Manufacturing capacity expansion initiatives
4️⃣ 7. Baxter International Inc.
Headquarters: Deerfield, IL, USA
Key Offering: Gammagard, HyQvia, BioTherapeutics
Baxter’s BioScience division delivers immunotherapies through 10+ manufacturing sites, offering both hospital-administered and home-based treatment options.
Therapeutic Advancements:
- Hybrid immunoglobulin replacement products
- Patient training programs for self-administration
- Next-gen cold-chain logistics solutions
3️⃣ 8. Green Cross Corp.
Headquarters: Yongin, South Korea (U.S. HQ in Montreal, Canada)
Key Offering: Green Gene-IQ, IVIg-SN, Albutein
Green Cross has advanced its North American market position through technology transfer agreements and expanded plasma fractionation capacity.
Therapeutic Advancements:
- Pathogen inactivation technologies
- Lyophilized immunoglobulin formulations
- Global clinical trial network expansion
2️⃣ 9. LFB S.A.
Headquarters: Les Ulis, France (U.S. HQ in Framingham, MA)
Key Offering: Nanogam, Flebogamma, Haemate P
LFB is Europe’s third-largest plasma products manufacturer, with growing immunoglobulin sales in North America through distribution partnerships.
Therapeutic Advancements:
- High-purity fractionation techniques
- Bioanalytical characterization platforms
- Pipeline of next-gen plasma derivatives
1️⃣ 10. Bio Products Laboratory Ltd.
Headquarters: Elstree, UK (North America HQ in Durham, NC)
Key Offering: IVIg, Subcutaneous Ig, Specialty Coagulation
BPL has strengthened its U.S. presence through FDA approvals and expanded distribution, offering plasma-derived therapies for primary immunodeficiencies.
Therapeutic Advancements:
- Pathogen reduction technology development
- Extended half-life formulation research
- Rare disease therapeutic expansion
Get Full Report: North America Primary Immunodeficiency Diseases Treatment Market – View in Detailed Research Report
🌍 Market Outlook: Transforming Immune Deficiency Treatment
The North America primary immunodeficiency treatment landscape is evolving through scientific advancements in biologics and personalized medicine approaches. Emerging therapies are addressing unmet needs in antibody deficiencies and cellular immune disorders.
📈 Key Market Trends:
- Shift toward patient-preferred subcutaneous administration
- Development of extended half-life immunoglobulin products
- Advancements in gene therapy and stem cell transplantation
- Integration of diagnostic biomarkers for personalized treatment
Get Full Report: North America Primary Immunodeficiency Diseases Treatment Market – View in Detailed Research Report
The profiled companies represent the vanguard of immune deficiency treatment innovation, driving improved outcomes through therapeutic advances and comprehensive patient support systems.
